¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Oxygen Permeable Lens Products Misc"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fraction of inspired oxygen
    ÈíÀÔ»ê¼Ò³óµµ
  • heavy oxygen
    Áß»ê¼Ò
  • hemoglobin oxygen saturation
    Çì¸ð±Û·Îºó»ê¼ÒÆ÷È­µµ
  • hyperbaric oxygen
    °í¾Ð»ê¼Ò
  • hyperbaric oxygen therapy
    °í¾Ð»ê¼Ò¿ä¹ý
  • inspired oxygen fraction
    µé¼û»ê¼ÒºÐÀ², Èí±â»ê¼ÒºÐÀ²
  • liquid oxygen
    ¾×ü»ê¼Ò
  • maximum oxygen debt
    ÃÖ´ë»ê¼ÒºÎä
  • mean venous oxygen content
    Æò±ÕÁ¤¸ÆÇ÷»ê¼Ò·®
  • oxygen
    »ê¼Ò
  • oxygen aeration
    »ê¼ÒÅë±â
  • oxygen consumption
    »ê¼Ò¼Ò¸ð
  • oxygen content
    »ê¼ÒÇÔÀ¯·®
  • oxygen debt
    »ê¼ÒºÎä
  • oxygen demand
    »ê¼Ò¿ä±¸·®
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • arterial oxygen saturation
    µ¿¸ÆÇ÷»ê¼ÒÆ÷È­µµ
  • oxygen saturation
    »ê¼ÒÆ÷È­µµ
  • arterial oxygen tension
    µ¿¸ÆÇ÷»ê¼ÒºÐ¾Ð
  • home oxygen therapy
    °¡Á¤»ê¼Ò¿ä¹ý
  • oxygen tension
    »ê¼ÒºÐ¾Ð, »ê¼ÒÀå·Â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • oxygen collar
    »ê¼Ò°í¸®
  • oxygen consumption
    »ê¼Ò¼Ò¸ð
  • oxygen content
    »ê¼ÒÇÔÀ¯·®
  • dissolved oxygen
    ¿ëÇØ»ê¼Ò
  • dissolved oxygen determination
    ¿ëÁ¸»ê¼Ò·®ÃøÁ¤, ³ìÀº»ê¼Ò·®ÃøÁ¤
  • maximum oxygen debt
    ÃÖ´ë»ê¼ÒºÎä·®
  • oxygen debt
    »ê¼ÒºÎä
  • oxygen demand
    »ê¼Ò¿ä±¸·®
  • total oxygen demand
    ¿Â»ê¼Ò¿ä±¸·®
  • inspired oxygen fraction
    Èí±â»ê¼ÒºÐÀ²
  • oxygen gain factor
    »ê¼ÒÀ̵æ°è¼ö
  • heavy oxygen
    Áß»ê¼Ò
  • hyperbaric oxygen
    °í¾Ð»ê¼Ò
  • oxygen hood
    »ê¼Ò¸Ó¸®µ¤°³, »ê¼ÒÈĵå
  • oxygen fixation hypothesis
    »ê¼Ò°íÁ¤°¡¼³
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • arterial oxygen content
    µ¿¸ÆÇ÷»ê¼ÒÇÔÀ¯·®
  • arterial oxygen saturation
    µ¿¸ÆÇ÷ »ê¼ÒÆ÷È­µµ
  • arterial oxygen tension
    µ¿¸ÆÇ÷»ê¼ÒºÐ¾Ð, µ¿¸ÆÇ÷»ê¼ÒÀå·Â
  • arterial oxygen tension
    µ¿¸ÆÇ÷ »ê¼ÒºÐ¾Ð
  • arterial-venous oxygen content difference
    µ¿¸Æ-Á¤¸Æ»ê¼Ò¿ëÀûÂ÷ÀÌ
  • arterial-venous oxygen difference
    µ¿¸Æ-Á¤¸Æ »ê¼ÒÂ÷ÀÌ
  • arteriovenous oxygen content difference
    µ¿Á¤¸ÆÇ÷ »ê¼ÒÇÔ·®Â÷
  • arteriovenous oxygen difference
    µ¿Á¤¸ÆÇ÷ »ê¼Ò±³Â÷(¡­úìß«áÈÎòó¬)
  • arteriovenous oxygen tension difference
    µ¿Á¤¸ÆÇ÷ »ê¼ÒºÐ¾ÐÂ÷
  • heavy oxygen
    Áß»ê¼Ò(ñìß«áÈ).
  • hyperbaric oxygen
    °í¾Ð»ê¼Ò
  • hyperbaric oxygen therapy
    °í¾Ð»ê¼Ò¿ä¹ý
  • ideal alveolar oxygen tension
    ÀÌ»ó(Àû)ÆóÆ÷ »ê¼ÒÀå·Â(ìµßÌîÜøËøàß«áÈíåæ³).
  • inspired oxygen fraction
    Èí±â»ê¼ÒºÐÀ²
  • Abraham iridotomy lens
    ¿¡À̺귯ÈìȫäÀý°³·»Áî
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • arterial blood oxygen tension
    µ¿¸ÆÇ÷»ê¼Ò Àå·Â.
  • arterial oxygen content
    µ¿¸ÆÇ÷»ê¼ÒÇÔÀ¯·®
  • arterial oxygen saturation
    µ¿¸ÆÇ÷ »ê¼ÒÆ÷È­µµ
  • arterial oxygen tension
    µ¿¸ÆÇ÷»ê¼ÒºÐ¾Ð, µ¿¸ÆÇ÷»ê¼ÒÀå·Â
  • arterial oxygen tension
    µ¿¸ÆÇ÷ »ê¼ÒºÐ¾Ð
  • arterial-venous oxygen content difference
    µ¿¸Æ-Á¤¸Æ»ê¼Ò¿ëÀûÂ÷ÀÌ
  • arterial-venous oxygen difference
    µ¿¸Æ-Á¤¸Æ »ê¼ÒÂ÷ÀÌ
  • arteriovenous oxygen content difference
    µ¿Á¤¸ÆÇ÷ »ê¼ÒÇÔ·®Â÷
  • arteriovenous oxygen difference
    µ¿Á¤¸ÆÇ÷ »ê¼Ò±³Â÷(¡­úìß«áÈÎòó¬)
  • arteriovenous oxygen tension difference
    µ¿Á¤¸ÆÇ÷ »ê¼ÒºÐ¾ÐÂ÷
  • biochemical oxygen demand =BOD
    »ý¹°È­ÇÐÀû »ê¼Ò¿ä±¸(·®)(ÊÙË×ËÛËíË´Ëâ).
  • biological oxygen demand =BOD
    »ý¹°ÇÐÀû »ê¼Ò¿ä±¸·®(ÊÙË×ËÛËíË´Ëâ).
  • biological oxygen demand =BOD
    »ý¹°ÇÐÀû »ê¼Ò¿ä±¸·®(¡­ß«áÈé©Ï´åÖ).
  • cardiac oxygen consumption
    ½ÉÀå»ê¼Ò¼Ò¸ð·®(ãýíôß«áÈá¼ÙÄÕá)
  • chemical oxygen demand =COD
    È­ÇÐÀû »ê¼Ò¿ä±¸·®(ÊÙË×ËÛËíË´Ëâ).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Deep lens epithelium
    ±íÀº¼öÁ¤Ã¼»óÇÇ
    [¿¾ ¿ë¾î] ½É¼öÁ¤Ã¼»óÇÇ
  • Epithelium of lens
    ¼öÁ¤Ã¼»óÇÇ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼»óÇÇ
  • Lens epithelium
    ¼öÁ¤Ã¼»óÇÇ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼»óÇÇ
  • Fibers of lens
    ¼öÁ¤Ã¼¼¶À¯
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼¼¶À¯
  • Lens fiber
    ¼öÁ¤Ã¼¼¶À¯
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼¼¶À¯
  • Lens vesicle
    ¼öÁ¤Ã¼¼ÒÆ÷
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼¼ÒÆ÷
  • Lens vesicle
    ¼öÁ¤Ã¼¼ÒÆ÷
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼Æ÷
  • Cortex of lens
    ¼öÁ¤Ã¼°ÑÁú
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼ÇÇÁú
  • Lens suture
    ¼öÁ¤Ã¼ºÀÇÕ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼ºÀÇÕ
  • Nucleus of lens
    ¼öÁ¤Ã¼ÇÙ
    [¿¾ ¿ë¾î] ¼öÁ¤Ã¼ÇÙ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • oxygen transport
    »ê¼Ò¿î¹Ý(ß«áÈê¡Úæ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ERPC evacuation of retained products of conception
FbDP fibrin degradation products
FgDP fibrinogen degradation products
SPF skin protection factor; specific-pathogen free; spectrophotofluorometer; S-phase fraction; split pro...
TDP thermal death point; thoracic duct pressure; thymidine diphosphate; total degradation products
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LCA Lens Culinaris
LOCS II Lens Opacities Classification System II
LEC lens epithelial cell
MIOL multifocal intraocular lens
PC IOL posterior chamber intraocular lens
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • oxygen dissociation curve
    »ê¼Ò ÇØ¸® °î¼±
  • oxygen lack
    »ê¼Ò ºÎÁ·, »ê¼Ò °áÇÌ
  • oxygen poisoning
    »ê¼Ò Áßµ¶, »ê¼Ò Áßµ¶Áõ
    °í³óµµ »ê¼ÒÀÇ Àå±â°£ ÈíÀÔÀ¸·Î »ý±â´Â Æó ½ÇÁúÀÇ ½ÉÇÑ Àå¾Ö.
  • oxygen probe
    »ê¼Ò Žħ
  • oxygen reserve
    »ê¼Ò ¿¹ºñ
  • oxygen saturaon curve
    »ê¼Ò Æ÷È­ °î¼±
  • oxygen secretion
    »ê¼Ò ºÐºñ
  • oxygen supply equipment
    »ê¼Ò °ø±Þ ÀåÄ¡
  • oxygen tension
    »ê¼Ò Àå·Â
  • oxygen toxicity
    »ê¼Ò µ¶¼º
  • oxygen transport mechanism
    »ê¼Ò ¿î¹Ý ±âÀü
  • oxygen uptake
    »ê¼Ò ¼·Ãë, »ê¼Ò ¼·Ãë·®
  • oxygen want
    »ê¼Ò ºÎÁ·, »ê¼Ò °áÇÌ, »ê¼Ò ¿ä±¸
  • transport oxygen
    »ê¼Ò ¿î¹Ý
  • anterior chamber intraocular lens
    Àü¹æ ·»Áî
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
glycosylation end products, advanced Products derived from the nonenzymatic reaction of glucose and proteins in vivo that exhibit a yellow-brown pigmentation and an ability to participate in protein-protein cross-linking. These substances are involved in biological processes relating to protein turnover and it is believed that their excessive accumulation contributes to the chronic complications of diabetes mellitus.
(12 Dec 1998)
waste products Debris resulting from a process that is of no further use to the system producing it. The concept includes materials discharged from or stored in a system in inert form as a by-product of vital activities.
(12 Dec 1998)
conventional forest products Any commercial roundwood product (boards, dimension lumber, pulp and paper products) except fuelwood.
(05 Dec 1998)
poultry products Food products manufactured from poultry.
(12 Dec 1998)
household products Substances or materials used in the course of housekeeping or personal routine.
(12 Dec 1998)
specialty chemicals and products Chemicals and chemical products used in a research, industrial, or household setting. Included here are the specific drug preparations, as well as the substances involved in the manufacture and stabilization of pharmaceutical preparations and agricultural agents.
(12 Dec 1998)
natural products Naturally occurring compounds that are end products of secondary metabolism; often, they are unique compounds for particular organisms or classes of organisms.
(05 Mar 2000)
dairy products Raw and processed or manufactured milk and milk-derived products. These are usually from cows (bovine) but are also from goats, sheep, reindeer, and water buffalo.
(12 Dec 1998)
orphan products Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in common or rare diseases but which are not considered commercially viable.
Synonym: orphan drugs.
(05 Mar 2000)
fibrin degradation products <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot.
Normal value is less than 10 mcg/ml (micrograms per millilitre).
They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia.
Acronym: FDP
(23 Sep 2002)
fibrin fibrinogen degradation products <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis.
Pharmacological action: antithrombins.
(12 Dec 1998)
fish products Food products manufactured from fish (e.g., fish flour, fish meal).
(12 Dec 1998)
alactic oxygen debt That part of the oxygen debt that is not lactacid oxygen debt; during recovery, stores of ATP and creatine phosphate must be replenished by oxidative metabolism, and a small amount of oxygen is also needed to restore the normal oxyhemoglobin levels throughout the circulating blood.
(05 Mar 2000)
alveolar-arterial oxygen difference The difference or gradient between the partial pressure of oxygen in the alveolar spaces and the arterial blood: P(A-a)02. Normally in young adults this value is less than 20 mm Hg.
See: alveolar gas equation.
(05 Mar 2000)
arteriovenous oxygen difference <physiology> The difference in the oxygen content (in ml per 100 ml blood) between arterial and venous blood.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • crytalline lens
    (´«¾ËÀÇ)¼öÁ¤Ã¼
  • diverging lens
    (±¤)¹ß»ê ·»Áî
  • electron lens
    ÀüÀÚ ·»Áî
  • eye lens
    ´ë¾È(Á¢¾È)·»Áî
  • field lens
    ´ë¹° ·»Áî;½Ã¿ª ·»Áî
  • haptic lens
    °ø¸· ·»Áî(¹é¾ÈºÎ)±îÁö µ¤´Â ÄÜÅÃÆ® ·»Áî)
  • lens
    ·»Áî;(´«¾ËÀÇ) ¼öÁ¤Ã¼
  • lens hood
    Ä«¸Þ¶óÈĵå
  • microcorneal lens
    ¼Ò°¢¸· ·»Áî(°¢¸·¸¸À» µ¤´Â ÄÜÅÃÆ®·»Áî)
  • object lens
    =OBJECT CLASS
  • positive lens
    Á¤·»Áî
  • progressive lens
    ÇÁ·Î±×·¹½Ãºê ·»Áî(2Áß ¶Ç´Â ´ÙÁß ÃÊÁ¡ ·»Áî)
  • zoom lens
    ÁÜ ·»Áî;°æµ¿ÀÇ ½ÅÃàÀ¸·Î ÃÊÁ¡°Å¸®;»ç°¢À» ÀÚÀ¯·Ó°Ô Á¶ÀýÇÒ ¼ö ÀÖ´Â ·»Áî
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á